Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$22.05 USD
+0.67 (3.13%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $22.10 +0.05 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BEAM 22.05 +0.67(3.13%)
Will BEAM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Brian's Big Idea on Healthcare
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
Other News for BEAM
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Beam Therapeutics: A Strong Buy on Gene Editing Advancements and Strategic Growth Potential
Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing
First Week of June 21st Options Trading For Beam Therapeutics (BEAM)